Medical Transdermal Drug Delivery Patches sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Medical Transdermal Drug Delivery Patches
1.1 - About Medical Transdermal Drug Delivery Patches sector
Companies in Medical Transdermal Drug Delivery Patches design and manufacture patch-based systems that deliver small molecules, hormones, and select biologics through the skin. They combine device engineering with formulation expertise to enable controlled, non‑invasive dosing, improving adherence and reducing clinical burden. Strategic buyers in this category typically offer end‑to‑end development, regulatory support, and GMP production to bring patch therapeutics to market.
Offerings span matrix and reservoir transdermal patch design, microneedle arrays for vaccines and peptides, and iontophoretic delivery for on‑demand dosing. Vendors engineer medical‑grade adhesives and backing layers, optimize permeation enhancers and polymers for controlled release, and run IVPT and PK modeling to tune profiles. Many provide combination‑product regulatory services, human factors testing, clinical trial kit assembly, and scalable GMP manufacturing with sterile packaging.
Primary customers include pharmaceutical manufacturers, biotech developers, and medical device OEMs pursuing transdermal delivery options. These companies help buyers achieve improved patient adherence, reduced reliance on injections, predictable pharmacokinetics with steady plasma levels, and faster time‑to‑market through integrated development and compliant production. Outcomes often include lower total cost of care and differentiated lifecycle strategies for new and reformulated therapies.
2. Buyers in the Medical Transdermal Drug Delivery Patches sector
2.1 Top strategic acquirers of Medical Transdermal Drug Delivery Patches companies
scPharmaceuticals
HQ: United States
Website
- Description: Provider of subcutaneous drug-delivery therapies aimed at improving outpatient care, commercializing FUROSCIX—a fixed-dose subcutaneous furosemide auto-injector for heart-failure-related fluid overload—and advancing investigational subcutaneous delivery platforms such as ceftriaxone.
- Key Products:
- FUROSCIX (Furosemide Injection): Proprietary subcutaneous diuretic delivered via fixed-dose auto-injector that treats fluid-overload congestion in heart-failure adults, enabling convenient outpatient self-administration instead of hospital IV therapy
- Subcutaneous Ceftriaxone (Investigational): Experimental subcutaneous antibiotic delivery platform in development to allow simplified on-body ceftriaxone infusion for outpatient infection treatment without intravenous hospital stays.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Medical Transdermal Drug Delivery Patches sector
M&A buyer group 1: Drug Delivery
24 companies
View group →
Description: Companies in the Life Sciences Drug Delivery Technologies category design and supply platforms that optimize how therapeutics are formulated, transported, and released. For analysts profiling strategic buyers in drug delivery technologies, these vendors enable improved bioavailability, targeted tissue access, and patient-friendly administration across small molecules, biologics, and RNA medicines. By combining formulation science with drug‑device integration and scalable manufacturing, they help sponsors advance pipelines and extend product life cycles.
Acorda
HQ: United States
- Type: N/A
- Employees: ●●●●●
- Description: Provider of biotechnology therapies aimed at restoring neurological function for people with nervous system disorders. The company researches, develops and commercializes treatments for multiple sclerosis, spinal cord injury, stroke, epilepsy and is advancing a therapeutic approach for chronic heart failure, collaborating with patient, medical and scientific communities to deliver innovative medicines.
- Key Products:
- Ampyra®: Oral sustained-release formulation of 4-aminopyridine that blocks potassium channels to improve walking ability in multiple-sclerosis patients, providing symptomatic neurological improvement
- Parkinson’s disease therapy program: R&D effort creating drug candidates that aim to restore neurological function and relieve motor symptoms in Parkinson’s through proprietary small-molecule approaches
- Migraine therapy program: Development of pharmacological treatments designed to reduce migraine frequency and severity by targeting neuronal signaling pathways related to neurological dysfunction
- Sustained-release 4-aminopyridine technology: Drug-delivery platform covered by patents enabling controlled release of 4-aminopyridine to maintain therapeutic plasma levels for extended neurological benefit.
🔒
🔒
🔒
View all 24 companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms in Medical Transdermal Drug Delivery Patches sector
3.1 - Buyout funds in the Medical Transdermal Drug Delivery Patches sector
2.2 - Strategic buyer groups for Medical Transdermal Drug Delivery Patches sector
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Medical Transdermal Drug Delivery Patches companies
4.2 - Public trading comparable groups for Medical Transdermal Drug Delivery Patches sector
Valuation benchmark group 1: Injectable Drug Delivery Manufacturers
3 companies
View group →
Description: Companies in this trading comparable group manufacture and supply parenteral drug packaging and delivery systems, spanning glass containment (vials, cartridges, prefillable syringes, ampoules) and injectable device platforms (autoinjectors, pens, targeted infusion systems), plus supporting inspection and assembly solutions. They are comparable given shared GMP manufacturing, regulatory validation cycles, embedded supply agreements with pharma/biotech, and revenue models tied to drug launches and lifecycle volumes, yielding similar margin structures and capital intensity.
Stevanato Group
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of integrated systems, processes, and services for the pharmaceutical and healthcare industries, specializing in glass primary packaging, drug delivery devices, and assembly and packaging equipment. Offers comprehensive solutions to ensure the integrity and safety of medications through advanced technologies and engineering excellence.
- Key Products:
- Precision Glass Forming: Advanced glass forming lines for pharmaceutical packaging
- Vision Inspection Systems: Equipment for inspecting drug containment solutions
- Drug Delivery Devices: Production of autoinjectors, pen injectors, and wearable injectors
- Assembly and Packaging: Solutions for efficient assembly and packaging of medical products
- Pre-Sterilized Containers: EZ-fill® technology for ready-to-use drug packaging solutions.
🔒
🔒
🔒
View all 3 companies in this group
Request Free Trial Now →
🔒
Revenue growth
Median
15.7%
2025E
16.0%
2026E
EBITDA margin
Median
28.2%
2025E
28.6%
2026E
Cash EBITDA margin
Median
27.6%
2025E
28.0%
2026E
EV/Revenue
Median
8.4x
2025E
6.8x
2026E
EV/EBITDA
Median
28.9x
2025E
24.4x
2026E
EV/Cash EBITDA
Median
29.0x
2025E
25.5x
2026E
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →